Precision Biosensor, Inc. (KOSDAQ:335810)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,732.00
-42.00 (-2.37%)
At close: Jun 5, 2026
Market Cap38.02B +28.1%
Revenue (ttm)22.34B +14.0%
Net Income-7.87B
EPS-543.79
Shares Out 21.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,806
Open1,890.00
Previous Close1,774.00
Day's Range1,702.00 - 1,890.00
52-Week Range1,700.00 - 4,500.00
Beta0.31
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About Precision Biosensor

Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea. [Read more]

Industry Measuring and Controlling Devices, not elsewhere classified
Founded 2009
Employees 98
Stock Exchange KOSDAQ
Ticker Symbol 335810
Full Company Profile

Financial Performance

In 2025, Precision Biosensor's revenue was 19.93 billion, an increase of 4.14% compared to the previous year's 19.13 billion. Losses were -10.02 billion, 37.2% more than in 2024.

Financial Statements